San Diego, California
January 13, 2009
Illumina, Inc. (NASDAQ:ILMN) today announced that it
has filed a patent infringement suit against
Affymetrix, Inc.
(“Affymetrix”). The suit, filed in United States District Court
for the Western District of Wisconsin, asserts that Affymetrix’
GeneChip® HT Array Plate and GeneChip® HT Array Plate Scanner
infringe upon Illumina’s United States Patent No. 7,510,841. The
‘841 patent, which issued on March 31, 2009, is entitled
“Methods of Making and Using Composite Arrays for the Detection
of a Plurality of Target Analytes.” Illumina is asking the
federal court to enjoin Affymetrix from continuing to make and
sell its HT Array Plate and Scanner products, as well as for
unspecified monetary damages.
Illumina is a leading
developer, manufacturer, and marketer of next-generation
life-science tools and integrated systems for the analysis of
genetic variation and biological function. Using our proprietary
technologies, we provide a comprehensive line of products and
services that currently serve the sequencing, genotyping, and
gene expression markets, and we expect to enter the market for
molecular diagnostics. Our customers include leading genomic
research centers, pharmaceutical companies, academic
institutions, clinical research organizations, and biotechnology
companies. Our tools provide researchers around the world with
the performance, throughput, cost effectiveness, and flexibility
necessary to perform the billions of genetic tests needed to
extract valuable medical information from advances in genomics
and proteomics. We believe this information will enable
researchers to correlate genetic variation and biological
function, which will enhance drug discovery and clinical
research, allow diseases to be detected earlier, and permit
better choices of drugs for individual patients. |
|
